Host-pathogen Interactions During SARS-CoV-2 Infection (HPI-COVID-19)

Civil Hospices of Lyon logo

Civil Hospices of Lyon

Status

Completed

Conditions

Infection, Coronavirus
Severe Acute Respiratory Syndrome Coronavirus 2

Treatments

Biological: Stool collection or fecal swab
Biological: Low or upper respiratory tract sample
Other: phone call
Biological: Blood sample

Study type

Interventional

Funder types

Other

Identifiers

NCT04376476
2020-A01102-37 (Other Identifier)
69HCL20_0342

Details and patient eligibility

About

The new Severe acute respiratory syndrome coronavirus (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) is currently responsible for a pandemic spread of febrile respiratory infections, responsible for a veritable global health crisis. In adults, several evolutionary patterns are observed: i) a/pauci-symptomatic forms; ii) severe forms immediately linked to rare extensive viral pneumonia; and iii) forms of moderate severity, some of which progress to secondary aggravation (Day 7-Day 10). Children can be affected, but are more rarely symptomatic and severe pediatric forms are exceptional. Like some other coronaviruses (SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV)), these differences in clinical expression could be based on a variability in the immunological response, notably either via inhibition of the type I interferon (IFN-I) response, or on the contrary an immunological dysregulation responsible for a "cytokine storm" associated with the aggravation. Little is known about the impact of these innate immune response abnormalities on the adaptive response. In addition, certain genetic factors predisposing to a state of "hyper-fragility" and certain viral virulence factors could also be predictive of the clinical response. In this context, the main hypothesis is that the virological analysis and the initial biological and immunological profiles are correlated with the initial clinical presentation of COVID-19 infection. In particular, children forms and pauci-symptomatic disease in adults may be linked to a more robust innate immune response, including better production of IFN-I.

Enrollment

140 patients

Sex

All

Ages

1 day to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Group E1:

  • Age from birth to <18 years old;
  • Weight> 3 kilogram (kg);
  • Infection with SARS-CoV-2 virus confirmed by RT-PCR on upper respiratory tract sample
  • No fever or respiratory symptoms;
  • Not requiring hospitalization (or hospitalization not related to a SARS-CoV-2 infection);
  • Consent signed by at least one parent / holder of parental authority and assent of the child (if applicable);
  • Beneficiary of a social security scheme

Group E2:

  • Age from birth to <18 years old;
  • Weight> 3kg;
  • Infection with the SARS-CoV-2 virus confirmed by RT-PCR on a upper or low respiratory tract sample or pneumonia with scanner suggesting SARS-CoV-2 infection;
  • Hospitalized in a pediatric intensive care unit or in a general pediatrics unit
  • Consent signed by at least one parent / holder of parental authority and assent of the child (if applicable);
  • Beneficiary of a social security scheme

Group E3:

  • Age from birth to <18 years old;
  • Weight> 3 kg;
  • Negative SARS-CoV-2 PCR on at least one respiratory sample, and other confirmed viral infection
  • Hospitalized in a pediatric intensive care unit or in a general pediatrics unit, for a respiratory reason;
  • Consent signed by at least one parent / holder of parental authority and assent of the child (if applicable);
  • Beneficiary of a social security scheme

Exclusion criteria

Group E1:

  • Patients with any other inherited or acquired immune deficiency that could compromise the immunological evaluation;
  • Other Suspected or proved infection
  • Pregnancy.

Group E2:

  • Patients with any other inherited or acquired immune deficiency that could compromise the immunological evaluation;
  • Pregnancy.

Group E3:

  • Patients with any other inherited or acquired immune deficiency that could compromise the immunological evaluation;
  • Infection with the SARS-CoV-2 virus known among the relatives
  • Pregnancy.

Trial design

140 participants in 3 patient groups

Children group E1
Experimental group
Description:
Children with confirmed asymptomatic or pauci-symptomatic COVID infection will be recruited in pediatric emergency departments, among siblings of COVID-19+ pediatric patients or through the blood collection centers set up by the occupational health services. A single visit will be scheduled at the hospital (for clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
Treatment:
Biological: Blood sample
Other: phone call
Biological: Low or upper respiratory tract sample
Children group E2
Experimental group
Description:
Children with confirmed COVID-19 infection requiring hospitalization will be recruited within participating centers (mostly in emergency and intensive care units). Data will be recorded (clinical examination, biology, immunology, virology measurements) during their hospital stay (day 0, day 7, in case of worsening) and a phone call performed at day 14 (or onsite visit if patient still hospitalized).
Treatment:
Biological: Blood sample
Biological: Low or upper respiratory tract sample
Biological: Stool collection or fecal swab
Children group E3
Experimental group
Description:
Children with confirmed non-COVID-19 viral infection requiring hospitalization will be recruited within participating centers (mostly in intensive care units). At inclusion, data will be recorded (clinical examination, biology, immunology, virology measurements) and a phone call performed at day 14.
Treatment:
Biological: Blood sample
Other: phone call
Biological: Low or upper respiratory tract sample
Biological: Stool collection or fecal swab

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems